Erythema, Lipidome, Microbiome, Side Effect, Skin Pigment, Wrinkle Appearance
Conditions
Keywords
Ginger, Curcumin, Zingerone
Brief summary
Cosmeceuticals are an emerging market within dermatology and the growth of natural products and derivatives of natural products has accelerated in use within the field. Here the investigators aimed to study the microbial and cosmetic effects of Synoxyl AZ, the trade name for topical acetyl zingerone (AZ), a novel compound designed based on Zingerone and curcumin.
Detailed description
Cosmeceuticals are an emerging market within dermatology and the growth of natural products and derivatives of natural products has accelerated in use within the field. Here the investigators aim to study Synoxyl AZ, the trade name for topical acetyl zingerone (AZ), a novel compound designed based on Zingerone and curcumin. Both curcumin and Zingerone are from the Zingiberacea family of plants (also known as the ginger family). Both have been widely studied and noted to have antibacterial effects and promote skin health effects. Curcumin has been studied widely in recent years due to various microbial effects. AZ is a derivative that is similar to both Zingerone and curcumin and has been noted to have many different activities including anti-inflammatory, antimicrobial, and antioxidant functions. However, there are no studies looking at how it modulates the skin cosmetically or the superficial microbiome. The aim of this study was to compare the cosmetic effects of AZ to a vehicle over an 8-week period.
Interventions
Topical cream with an active acetyl zingerone component.
Topical cream without an active acetyl zingerone component and just the carrier cream.
Sponsors
Study design
Masking description
Double blind
Intervention model description
Subjects will be randomized to two groups: AZ Group (n= 17) Control Group (n=17)
Eligibility
Inclusion criteria
* Individuals aged 30-60 * Healthy subjects
Exclusion criteria
* Those that have had topical antibiotics within the past 4 weeks * Those that have had oral antibiotics within past 4 weeks * Those who have used systemic isotretinoin in the last 6 months * Those with a known allergy to members of the ginger family * Current smokers OR 20 pack-year history of smoking OR Have smoked within the past 3 years * Pregnant women * Prisoners * Those who have had any change to their hormonal birth control regimen in the last 4 weeks. * Those with visible signs in the area of application of or on active treatment for cystic acne, eczema, seborrheic dermatitis, papulopustular rosacea at investigator discretion * Those who have had a recent surgical or cosmetic procedure in the last 3 months that can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin injections, chemical peels, laser based therapies to the face, or face lift surgeries at investigator discretion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in wrinkle appearance | 8 weeks | Change in image based analysis of wrinkle severity from baseline |
| Change in appearance of skin pigmentation | 8 weeks | Change in appearance of image based skin pigmentation from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in wrinkle appearance | 4 weeks | Change in image based analysis of wrinkle severity from baseline |
| Appearance of side effects such as scaling or irritation | 4 weeks and 8 weeks | Appearance of side effects such as scaling or irritation from baseline |
| Change in skin redness (erythema) | 4 weeks and 8 weeks | Change in image based skin redness (erythema) and clinical assessment of redness from baseline |
| Change in superficial lipidome diversity | 4 weeks and 8 weeks | Change in superficial lipidome diversity from basline |
| Change in superficial microbiome diversity | 4 weeks and 8 weeks | Change in superficial microbiome diversity from baseline |
| Change in appearance of skin pigmentation | 4 weeks | Change in appearance of image based skin pigmentation from baseline |
Countries
United States